|
|
 |
|
 |
|
| 1 |
Utsumi T, Kamiya N, Kaga M, Endo T, Yano M, Kamijima S, Kawamura K, Imamoto T,Ichikawa T, Suzuki H. Development of novel nomograms to predict renal functional outcomes after laparoscopic adrenalectomy in patients with primary aldosteronism.World J Urol. 2017 Oct;35(10):1577-1583. doi: 10.1007/s00345-017-2033-5. Epub 2017 Apr 11. PubMed PMID: 28401356.
|
| 2 |
Okato A, Arai T, Kojima S, Koshizuka K, Osako Y, Idichi T, Kurozumi A, Goto Y,Kato M, Naya Y, Ichikawa T, Seki N. Dual strands of pre-miR?150 (miR?150?5p and miR?150?3p) act as antitumor miRNAs targeting SPOCK1 in naive and castration-resistant prostate cancer. Int J Oncol. 2017 Jul;51(1):245-256. doi:10.3892/ijo.2017.4008. Epub 2017 May 17. PubMed PMID: 28534948.
|
| 3 |
Goto Y, Kurozumi A, Arai T, Nohata N, Kojima S, Okato A, Kato M, Yamazaki K,Ishida Y, Naya Y, Ichikawa T, Seki N. Impact of novel miR-145-3p regulatory networks on survival in patients with castration-resistant prostate cancer. Br J Cancer. 2017 Jul 25;117(3):409-420. doi: 10.1038/bjc.2017.191. Epub 2017 Jun 22. PubMed PMID: 28641312.
|
| 4 |
Kaga K, Inoue KI, Kaga M, Ichikawa T, Yamanishi T. Expression profile of urothelial transcription factors in bladder biopsies with interstitial cystitis. Int J Urol. 2017 Aug;24(8):632-638. doi: 10.1111/iju.13391. Epub 2017 Jun 18.PubMed PMID: 28626955.
|
| 5 |
Arai T, Okato A, Kojima S, Idichi T, Koshizuka K, Kurozumi A, Kato M, Yamazaki K, Ishida Y, Naya Y, Ichikawa T, Seki N. Regulation of spindle and kinetochore-associated protein 1 by antitumor miR-10a-5p in renal cell carcinoma.Cancer Sci. 2017 Oct;108(10):2088-2101. doi: 10.1111/cas.13331. Epub 2017 Aug 19.PubMed PMID: 28746769; PubMed Central PMCID: PMC5623743.
|
| 6 |
Okato A, Arai T, Yamada Y, Sugawara S, Koshizuka K, Fujimura L, Kurozumi A,Kato M, Kojima S, Naya Y, Ichikawa T, Seki N. Dual Strands of Pre-miR-149 Inhibit Cancer Cell Migration and Invasion through Targeting FOXM1 in Renal Cell Carcinoma. Int J Mol Sci. 2017 Sep 13;18(9). pii: E1969. doi:10.3390/ijms18091969. PubMed PMID:28902136; PubMed Central PMCID: PMC5618618.
|
| 7 |
Yamamoto S, Sakamoto S, Minhui X, Tamura T, Otsuka K, Sato K, Maimaiti M,Kamada S, Takei A, Fuse M, Kawamura K, Imamoto T, Komiya A, Akakura K, Ichikawa T. Testosterone Reduction of?? 480 ng/dL Predicts Favorable Prognosis of Japanese Men With Advanced Prostate Cancer Treated With Androgen-Deprivation Therapy. Clin Genitourin Cancer. 2017 Dec;15(6):e1107-e1115. doi: 10.1016/j.clgc.2017.07.023.Epub 2017 Aug 3. PubMed PMID: 28882738.
|
| 8 |
Kasuya G, Ishikawa H, Tsuji H, Haruyama Y, Kobashi G, Ebner DK, Akakura K,Suzuki H, Ichikawa T, Shimazaki J, Makishima H, Nomiya T, Kamada T, Tsujii H;Working Group for Genitourinary Tumors. Cancer-specific mortality of high-risk prostate cancer after carbon-ion radiotherapy plus long-term androgen deprivation therapy. Cancer Sci. 2017 Dec;108(12):2422-2429. doi: 10.1111/cas.13402. Epub 2017 Nov 3. PubMed PMID: 28921785; PubMed Central PMCID: PMC5715357.
|
| 9 |
Namekawa T, Utsumi T, Tanaka T, Kaga M, Nagano H, Kono T, Kawamura K, Kamiya N, Imamoto T, Suzuki H, Ichikawa T. Hypertension Cure Following Laparoscopic Adrenalectomy for Hyperaldosteronism is not Universal: Trends Over Two Decades.World J Surg. 2017 Apr;41(4):986-990. doi: 10.1007/s00268-016-3822-5. PubMed PMID: 27872977.
|
| 10 |
Takei A, Sakamoto S, Wakai K, Tamura T, Imamura Y, Xu M, Maimaiti M, Kawamura K, Imamoto T, Komiya A, Akakura K, Ichikawa T. Duration of androgen deprivation therapy and nadir of testosterone at 20 ng/dL predict testosterone recovery to supracastrate level in prostate cancer patients who received external beam diotherapy. Int J Urol. 2018 Jan 11. doi: 10.1111/iju.13521. [Epub ahead of print] PubMed PMID: 29323427.
|
| 11 |
Yamada Y, Nishikawa R, Kato M, Okato A, Arai T, Kojima S, Yamazaki K, Naya Y, Ichikawa T, Seki N. Regulation of HMGB3 by antitumor miR-205-5p inhibits cancer cell aggressiveness and is involved in prostate cancer pathogenesis. J Hum Genet. 2018 Feb;63(2):195-205. doi: 10.1038/s10038-017-0371-1. Epub 2017 Dec 1. PubMed PMID: 29196733.
|
| 12 |
Yamada Y, Sakamoto S, Shimazaki J, Sugiura M, Amiya Y, Sasaki M, Shima T, Komiya A, Suzuki N, Akakura K, Ichikawa T, Nakatsu H. Significant prognostic difference between Grade Group 4 and 5 in the 2014 International Society of Urological Pathology Grading System for High Grade Prostate Cancer with Bone Metastasis. Prostate Int. 2017 Dec;5(4):143-148. doi: 0.1016/j.prnil.2017.03.001. Epub 2017 Mar 16. PubMed PMID: 29188201; PubMed Central PMCID: PMC5693457.
|
| 13 |
Yamada Y, Arai T, Sugawara S, Okato A, Kato M, Kojima S, Yamazaki K, Naya Y, Ichikawa T, Seki N. Cancer Sci. 2018 Apr;109(4):1239-1253. doi: 10.1111/cas.13526. Epub 2018Mar9.PMID:29417701 Impact of novel oncogenic pathways regulated by antitumor miR-451a in renal cell carcinoma.
|
| 14 |
Arai T, Fuse M, Goto Y, Kaga K, Kurozumi A, Yamada Y, Sugawara S, Okato A, Ichikawa T, Yamanishi T, Seki N.J Hum Genet. 2018 May;63(5):543-554. doi:10.1038/s10038-018-0419-x. Epub 2018 Mar 12.PMID:29531336 Molecular pathogenesis of interstitial cystitis based on microRNA expression signature: miR-320 family-regulated molecular pathways and targets.
|
| 15 |
Takeuchi N, Sakamoto S, Nishiyama A, Horikoshi T, Yamada Y, Iizuka J, Maimaiti M, Imamura Y, Kawamura K, Imamoto T, Komiya A, Ikehara Y, Akakura K, Ichikawa T.Clin Genitourin Cancer. 2018 Feb 24. pii: S1558-7673(18)30127-7. doi: 10.1016/j.clgc.2018.02.011. [Epub ahead of print]PMID: 29576444 Biparametric Prostate Imaging Reporting and Data System version2 and International Society of Urological Pathology Grade Predict Biochemical Recurrence after Radical Prostatectomy.
|
| 16 |
Sugawara S, Yamada Y, Arai T, Okato A, Idichi T, Kato M, Koshizuka K, Ichikawa T, Seki N.J Hum Genet. 2018 May;63(5):657-668. doi: 10.1038/s10038-018-0437-8. Epub 2018 Mar 14.PMID:29540855 Dual strands of the miR-223 duplex (miR-223-5p and miR-223-3p) inhibit cancer cell aggressiveness: targeted genes are involved in bladder cancer pathogenesis.
|
| 17 |
Suetsugu T, Koshizuka K, Seki N, Mizuno K, Okato A, Arai T, Misono S, Uchida A, Kumamoto T, Inoue H. Downregulation of matrix metalloproteinase 14 by the antitumor miRNA, miR-150-5p, inhibits the aggressiveness of lung squamous cell carcinoma cells.
Int J Oncol. 2018 Mar;52(3):913-924. doi: 10.3892/ijo.2017.4232. Epub 2017 Dec 21.
PMID:29286099
|
| 18 |
Koshizuka K, Hanazawa T, Kikkawa N, Katada K, Okato A, Arai T, Idichi T, Osako Y, Okamoto Y, Seki N. Antitumor miR-150-5p and miR-150-3p inhibit cancer cell aggressiveness by targeting SPOCK1 in head and neck squamous cell carcinoma.
Auris Nasus Larynx. 2018 Aug;45(4):854-865. doi: 10.1016/j.anl.2017.11.019. Epub 2017 Dec 9.PMID:29233721
|
| 19 |
Takei A, Sakamoto S, Wakai K, Tamura T, Imamura Y, Xu M, Maimaiti M, Kawamura K, Imamoto T, Komiya A, Akakura K, Ichikawa T.Duration of androgen deprivation therapy and nadir of testosterone at 20 ng/dL predict testosterone recovery to supracastrate level in prostate cancer patients who received external beam radiotherapy.Int J Urol. 2018 Apr;25(4):352-358. doi: 10.1111/iju.13521. Epub 2018 Jan 11.PMID:29323427
|
| 20 |
Takeuchi N, Sakamoto S, Nishiyama A, Horikoshi T, Yamada Y, Iizuka J, Maimaiti M, Imamura Y, Kawamura K, Imamoto T, Komiya A, Ikehara Y, Akakura K, Ichikawa T.Biparametric Prostate Imaging Reporting and Data System version2 and International Society of Urological Pathology Grade Predict Biochemical Recurrence after Radical Prostatectomy.Clin Genitourin Cancer. 2018 Aug;16(4):e817-e829. doi: 10.1016/j.clgc.2018.02.011. Epub 2018 Feb 24. PMID:29576444
|
|
|
|
|
|
|
|
|
|
|
|
|
